Peer-reviewed veterinary case report
Epirubicin chemotherapy for treating lymphoma in dogs
By Elliott, J. W. et al.·Published in Veterinary and Comparative Oncology·2012·Small Animal Teaching Hospital University of Liverpool Wirral UK, United Kingdom·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Epirubicin as part of a multi‐agent chemotherapy protocol for canine lymphoma
- Species:
- dog
Plain-English summary
A group of 97 dogs with lymphoma received a combination chemotherapy treatment that included a drug called epirubicin. Most dogs (96%) showed a complete response to the treatment, with an average time to first relapse of about 216 days and an overall survival time of 342 days. While dogs with a specific type of lymphoma (T-cell lymphoma) had shorter survival times, the treatment was generally well tolerated and had similar side effects to other chemotherapy options. Overall, epirubicin proved to be a safe and effective choice for treating this serious condition in dogs.
People also search for: dog lymphoma treatment · epirubicin for dogs · canine chemotherapy side effects
Abstract
AbstractThe aim of the study was to report the outcome of treatment of 97 dogs with lymphoma that received a multi‐agent chemotherapy protocol containing epirubicin as the primary anthracycline. Seventy‐five dogs received a 25‐week protocol with no maintenance phase whilst 22 dogs received a maintenance phase. Complete response rate was 96% and time to first relapse (TTR) and overall survival (OS) time for all dogs were 216 and 342 days, respectively. Dogs with T‐cell lymphoma and those classified asWHOsubstage b had significantly poorer OS times and TTR. The protocol was well tolerated with toxicity similar to doxorubicin‐containing protocols. Epirubicin as part of a multi‐agent protocol is safe and effective in the treatment of canine multicentric lymphoma. There is a high initial response rate and an overall median survival time that is similar to other published doxorubicin‐containing protocols.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/j.1476-5829.2011.00311.x